{"id":471376,"date":"2021-04-06T06:53:19","date_gmt":"2021-04-06T10:53:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=471376"},"modified":"2021-04-06T06:53:19","modified_gmt":"2021-04-06T10:53:19","slug":"ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/","title":{"rendered":"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs<\/b><\/p>\n<p class=\"bwalignc\">\n&#8212; Accretive transaction in line with growth strategy laid out for Branded Products business &#8212;\n<\/p>\n<p>BAUDETTE, Minn.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nANI Pharmaceuticals, Inc. (\u201cANI\u201d) (NASDAQ:ANIP) today announced that it has acquired the new drug applications (\u201cNDAs\u201d) for OXISTAT<sup>\u00ae<\/sup> Lotion, VEREGEN<sup>\u00ae<\/sup> Ointment, and Pandel<sup>\u00ae<\/sup> Cream and the abbreviated new drug application (\u201cANDA\u201d) for ApexiCon<sup>\u00ae<\/sup> E Cream from Sandoz Inc. Pandel<sup>\u00ae<\/sup> Cream will be transitioned later upon receiving the requisite approvals. Collectively, these products generated net revenues of $13.2 million in 2020. The acquisition was funded through borrowings under the Company\u2019s pre-existing revolver credit facility.\n<\/p>\n<p>\nIn conjunction with the acquisition, ANI and Sandoz have entered into a multi-year manufacturing and supply agreement for OXISTAT<sup>\u00ae<\/sup> Lotion, Pandel<sup>\u00ae<\/sup> Cream and ApexiCon<sup>\u00ae<\/sup> E Cream. ANI intends to transfer the manufacture and packaging of these three products to its own manufacturing sites in the future.\n<\/p>\n<p>\n\u201cThis acquisition is in line with our strategy to expand our established brands business through accretive deals. Importantly, ANI will ensure that patients in need continue to receive these high-quality dermatology products. The acquisition leverages our innovative brand commercialization infrastructure and our North American manufacturing footprint,\u201d stated Nikhil Lalwani, President and CEO.\n<\/p>\n<p>\nThe Company previously shared the four pillars of its strategy for delivering sustainable future growth:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nBuild a successful Cortrophin franchise;\n<\/li>\n<li>\nStrengthen the Generics business by enhancing development capabilities and increased focus on niche opportunities;\n<\/li>\n<li>\nMaximize the value from established brands through programmatic business development and innovative access and go-to-market strategies; and\n<\/li>\n<li>\nExpand CDMO business leveraging unique North American-based manufacturing capabilities.\n<\/li>\n<\/ul>\n<p><b>About OXISTAT<sup>\u00ae<\/sup> (oxiconazole nitrate) Lotion 1%<\/b><\/p>\n<p>\nOXISTAT Lotion is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to <i>Trichophyton rubrum<\/i>, <i>Trichophyton mentagrophytes<\/i>, or <i>Epidermophyton floccosum<\/i>.\n<\/p>\n<p><b>About Pandel<sup>\u00ae<\/sup> (hydrocortisone probutate) Cream 0.1%<\/b><\/p>\n<p>\nPandel is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 18 years of age or older.\n<\/p>\n<p><b>About VEREGEN<sup>\u00ae<\/sup> (sinecatechins) Ointment 15%<\/b><\/p>\n<p>\nVEREGEN is a topical ointment indicated for the treatment of external genital and perianal warts (<i>Condylomata acuminata<\/i>) in immunocompetent patients 18 years and older.\n<\/p>\n<p><b>About ApexiCon<sup>\u00ae<\/sup> E Cream (diflorasone diacetate cream USP 0.05% [emollient])<\/b><\/p>\n<p>\nApexiCon E Cream is a topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.\n<\/p>\n<p>\nFor more information, including the complete list of indications and usages, please see the Full Prescribing Information.\n<\/p>\n<p><b>About ANI <\/b><\/p>\n<p>\nANI Pharmaceuticals, Inc. (the \u201cCompany\u201d or \u201cANI\u201d) is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company&#8217;s targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.anipharmaceuticals.com%2F&amp;esheet=52406495&amp;newsitemid=20210406005249&amp;lan=en-US&amp;anchor=www.anipharmaceuticals.com&amp;index=1&amp;md5=3c4e61ab504c5d8a97c2aacfd0ccc683\">www.anipharmaceuticals.com<\/a>.\n<\/p>\n<p><b>Forward-Looking Statements <\/b><\/p>\n<p>\nTo the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the Company&#8217;s strategy, the Company\u2019s future operations, products financial position, operating results and prospects, the Company\u2019s pipeline or potential markets therefor, and other statements that are not historical in nature, particularly those that utilize terminology such as \u201canticipates,\u201d \u201cwill,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201cfuture,\u201d \u201cbelieves,\u201d \u201cintends,\u201d \u201ccontinue,\u201d other words of similar meaning, derivations of such words and the use of future dates.\n<\/p>\n<p>\nUncertainties and risks may cause the Company\u2019s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may face with respect to transitioning these products; importing raw materials; increased competition; acquisitions; contract manufacturing arrangements; delays or failure in obtaining product approval from the U.S. Food and Drug Administration; general business and economic conditions; market trends; products development; regulatory and other approvals and marketing.\n<\/p>\n<p>\nMore detailed information on these and additional factors that could affect the Company\u2019s actual results are described in the Company\u2019s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as its proxy statement. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company\u2019s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005249r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210406005249\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210406005249\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Relations:<br \/>\n<br \/>Lisa M. Wilson, In-Site Communications, Inc.<br \/>\n<br \/>T: 212-452-2793<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DXTd8RaKkLtk5Jz54bM5Kloe23NibhBGr9CmdwBSbjo4obZ9AT6RJuEGdSq3R1omU_hCoBgYeDMYOetgWNW2KUxt-K7r0W5a6Pt_4PxgIdLI%3D&amp;esheet=52406495&amp;newsitemid=20210406005249&amp;lan=en-US&amp;anchor=lwilson%40insitecony.com&amp;index=2&amp;md5=88419039a935fee3db694272fa2eb657\">lwilson@insitecony.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Minnesota<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research FDA Other Health Biotechnology General Health Pharmaceutical Health Science Oncology Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs &#8212; Accretive transaction in line with growth strategy laid out for Branded Products business &#8212; BAUDETTE, Minn.&#8211;(BUSINESS WIRE)&#8211; ANI Pharmaceuticals, Inc. (\u201cANI\u201d) (NASDAQ:ANIP) today announced that it has acquired the new drug applications (\u201cNDAs\u201d) for OXISTAT\u00ae Lotion, VEREGEN\u00ae Ointment, and Pandel\u00ae Cream and the abbreviated new drug application (\u201cANDA\u201d) for ApexiCon\u00ae E Cream from Sandoz Inc. Pandel\u00ae Cream will be transitioned later upon receiving the requisite approvals. Collectively, these products generated net revenues of $13.2 million in 2020. The acquisition was funded through borrowings under the Company\u2019s pre-existing revolver credit facility. In conjunction with the acquisition, ANI and Sandoz have entered into a multi-year manufacturing and supply agreement &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-471376","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs &#8212; Accretive transaction in line with growth strategy laid out for Branded Products business &#8212; BAUDETTE, Minn.&#8211;(BUSINESS WIRE)&#8211; ANI Pharmaceuticals, Inc. (\u201cANI\u201d) (NASDAQ:ANIP) today announced that it has acquired the new drug applications (\u201cNDAs\u201d) for OXISTAT\u00ae Lotion, VEREGEN\u00ae Ointment, and Pandel\u00ae Cream and the abbreviated new drug application (\u201cANDA\u201d) for ApexiCon\u00ae E Cream from Sandoz Inc. Pandel\u00ae Cream will be transitioned later upon receiving the requisite approvals. Collectively, these products generated net revenues of $13.2 million in 2020. The acquisition was funded through borrowings under the Company\u2019s pre-existing revolver credit facility. In conjunction with the acquisition, ANI and Sandoz have entered into a multi-year manufacturing and supply agreement &hellip; Continue reading &quot;ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-06T10:53:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005249r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs\",\"datePublished\":\"2021-04-06T10:53:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/\"},\"wordCount\":813,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005249r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/\",\"name\":\"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005249r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-04-06T10:53:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005249r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005249r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/","og_locale":"en_US","og_type":"article","og_title":"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs - Market Newsdesk","og_description":"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs &#8212; Accretive transaction in line with growth strategy laid out for Branded Products business &#8212; BAUDETTE, Minn.&#8211;(BUSINESS WIRE)&#8211; ANI Pharmaceuticals, Inc. (\u201cANI\u201d) (NASDAQ:ANIP) today announced that it has acquired the new drug applications (\u201cNDAs\u201d) for OXISTAT\u00ae Lotion, VEREGEN\u00ae Ointment, and Pandel\u00ae Cream and the abbreviated new drug application (\u201cANDA\u201d) for ApexiCon\u00ae E Cream from Sandoz Inc. Pandel\u00ae Cream will be transitioned later upon receiving the requisite approvals. Collectively, these products generated net revenues of $13.2 million in 2020. The acquisition was funded through borrowings under the Company\u2019s pre-existing revolver credit facility. In conjunction with the acquisition, ANI and Sandoz have entered into a multi-year manufacturing and supply agreement &hellip; Continue reading \"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-06T10:53:19+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005249r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs","datePublished":"2021-04-06T10:53:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/"},"wordCount":813,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005249r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/","name":"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005249r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-04-06T10:53:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005249r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005249r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz-inc-ndas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=471376"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471376\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=471376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=471376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=471376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}